{"name":"Coherus BioSciences","slug":"coherus","ticker":"CHRS","exchange":"NASDAQ","domain":"coherus.com","description":"Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27. It also develops CHS-114, an investigational human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME) patients with head and neck squamous cell carcinoma. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreements with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biome","hq":"Redwood City, CA","founded":2015,"employees":"145","ceo":"Denny Lanfear","sector":"Biosimilars / Oncology","stockPrice":1.66,"stockChange":-0.05,"stockChangePercent":-2.92,"marketCap":"$256M","metrics":{"revenue":46883000,"revenueGrowth":62,"grossMargin":68.1,"rdSpend":108888000,"netIncome":168024000,"cash":88879000,"dividendYield":0,"peRatio":-2,"fiscalYear":"FY2018"},"revenueBreakdown":[],"timeline":[{"date":"2024-01-01","label":"Loqtorzi first approved","drug":"Loqtorzi","drugSlug":"toripalimab","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"Udenyca patent cliff ($1.4B at risk)","drug":"Udenyca","type":"patent_expiry","sentiment":"negative"},{"date":"2032-06-01","label":"Yutiq patent cliff ($1.1B at risk)","drug":"Yutiq","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Loqtorzi","genericName":"TORIPALIMAB","slug":"toripalimab","indication":"metastatic or recurrent locally advanced nasopharyngeal carcinoma (NPC)","status":"marketed"},{"name":"YUSIMRY","genericName":"ADALIMUMAB-AQVH","slug":"adalimumab-aqvh","indication":"Rheumatoid Arthritis","status":"marketed"}]}],"pipeline":[{"name":"Loqtorzi","genericName":"TORIPALIMAB","slug":"toripalimab","phase":"marketed","mechanism":"Loqtorzi blocks the PD-1 receptor, allowing the immune system to recognize and attack cancer cells.","indications":["metastatic or recurrent locally advanced nasopharyngeal carcinoma (NPC)","recurrent unresectable or metastatic NPC"],"catalyst":""},{"name":"YUSIMRY","genericName":"ADALIMUMAB-AQVH","slug":"adalimumab-aqvh","phase":"marketed","mechanism":"","indications":["Rheumatoid Arthritis","Juvenile Idiopathic Arthritis","Psoriatic Arthritis","Ankylosing Spondylitis","Crohn's Disease"],"catalyst":""}],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"FDA Approves Coherus BioSciences' Udenyca (pegfilgrastim-cbqv) for Neutropenia","summary":"The FDA has approved Udenyca (pegfilgrastim-cbqv) for the prevention of chemotherapy-induced neutropenia.","drugName":"Udenyca","sentiment":"positive"},{"date":"2023-11-07","type":"earnings","headline":"Coherus BioSciences Reports Third Quarter 2023 Financial Results","summary":"Coherus BioSciences reported revenue of $143.8 million for the third quarter of 2023, a 14% increase from the same period in 2022.","drugName":"","sentiment":"neutral"},{"date":"2023-09-01","type":"deal","headline":"Coherus BioSciences Announces Collaboration with Pfizer to Develop and Commercialize Biosimilars","summary":"Coherus BioSciences has entered into a collaboration with Pfizer to develop and commercialize biosimilars in the US and other countries.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-03-09","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-09","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-17","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxQWFhOWS1VOGxxSWFNclR6MUo1QUI4T3g1LWZqWFIwNl9abnB3dlRXUnQtQ0pzWnJsZ256X0tvMkZuLURsQ0M2OFI0VW81MmRCOEctV042eUU1UUE4VzhrUHFmbzlIeUZzcUZuX3hYUktXZVRJb1pHQnFaaEhobURQaFFFS3NiQ2ZIZXNxVFNNQzA?oc=5","date":"2026-02-05","type":"deal","source":"The Pharma Letter","summary":"Coherus Oncology announces deal with J&J - The Pharma Letter","headline":"Coherus Oncology announces deal with J&J","sentiment":"neutral"},{"date":"2026-02-04","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-01-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxPMUNZaTAzX292akxLdVctVG5hTFhJQnhzUG15TUhhc1dobHJUX0d5czNNUzNudFVxclRFdHFzeUUwU0xkaHRXSVd4Y0FZaFFfNXBQN2pXNlNvQ01abEVuSlBRbGNnZDlleF9PcUg5V3ZHYjFiLWZYeFF4UlhaWXhwcmVheW9zSzFYLUNManBCeEhITTMwRjV0a3d6Vk1wUzhHc3gxRlR2a3V1NGpSLUVqUkZRcVJVRkUzdkdfcWZUX216YjhoVUk3dEN3?oc=5","date":"2026-01-22","type":"pipeline","source":"Investing.com","summary":"Oppenheimer initiates Coherus Biosciences stock with Outperform rating - Investing.com","headline":"Oppenheimer initiates Coherus Biosciences stock with Outperform rating","sentiment":"neutral"},{"date":"2026-01-13","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-11-13","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxOaDZvZFV1YXNwbkJUa0RCQ3lpVGJiM2F2dDdqZ3pVVzl0NHJTVjZ5YktoXzRqVXhHNmZfZ1dGc3doNzJRS0VCanJLOTg4QTNuZjRBd1RTQlVWN012V1VTTEpiWklTU2dkYlZpcFhCSWluOG1FZ2pmRWdVU05UaEdfNE1TbDJ3VHlLTHU3Q1FIaERYc0RHd3ZLODEteVBkbmFMXzRHd0ZzNHFXaGhCYjUxcFBn?oc=5","date":"2025-04-17","type":"pipeline","source":"Seeking Alpha","summary":"Coherus: Cleaning The Balance Sheet And Developing New Drugs (NASDAQ:CHRS) - Seeking Alpha","headline":"Coherus: Cleaning The Balance Sheet And Developing New Drugs (NASDAQ:CHRS)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE0zSXB1UlpsVzg0NmNOVUQweG5OV1RoQ3dMOUZ3M1NBWVVjR0VQU2Z3LUxiTE9Oc2tFSGx5MzE2UTI3YVM4SmwzWmdVSXpvYnE1dFZaQWUwNk1IZWc0eXVfZGtvOGhUOFhkUjF5X08yOTlGbnRDcDJHUkFVRkhHUlE?oc=5","date":"2025-04-14","type":"pipeline","source":"The Pharma Letter","summary":"Coherus completes strategic transformation - The Pharma Letter","headline":"Coherus completes strategic transformation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxPY0U3Mk1UNFYwNUxzWEZCSThUdG5zVnFaZXk0UGM4NVlsdnRYOUJRZkM3dDd1SWIwZWtBUDhYN0ZQNHBUWGJBdlBkazhyZUZudjFELUlWUEZNdXRtRWVUQ1NQVGY1ME1uVzBUcEZlSmM3cHJaVE0tS25RbTFjeEtwUVl5ODRueXhZejRrV3lEOGFlX2M3aS02eG5mSHFyUlZ5Z0FYbTdaNkFCamdMc0RENmVQZVI2alk?oc=5","date":"2024-12-04","type":"pipeline","source":"Latham & Watkins LLP","summary":"Latham Watkins Advises Coherus in Divesture of UDENYCA Franchise to Intas Pharmaceuticals - Latham & Watkins LLP","headline":"Latham Watkins Advises Coherus in Divesture of UDENYCA Franchise to Intas Pharmaceuticals - Latham & Watkins LLP","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwJBVV95cUxPclpETWNOVmlwTHMtU1Q5S294bkxDTUNNalZERENISklfdlJOTm9yaUltd2NNZ2xfR1dOazBtbzF1N2Y2aXlfX2k1aUhNX1Nuc0R3WkZFNDEzdHpPUktQRHc0VmVhcXRFbFJ2M1FJODdqbngxRWxhcFN3NUlMMWJRUmgxR01DTEpGRUR3RWh2eXVFWW5tTWlTcTAtNmExMW1pY0lrbUkydjFkU1dZal90V3ZxVUZRQ2dRb0R2ZUM2SHd1dkF2SkN1bmF1LUx0RDVud2g3V285d3l1MGQtMGxXdUh0dEUyUUIwZk5BVGFDNHJjM1NrV0t0WWx1aE5mbTI1bHEyVkJnLXIxYm9UX3dN?oc=5","date":"2024-12-03","type":"pipeline","source":"GlobeNewswire","summary":"Coherus Announces Agreement to Divest UDENYCA® Franchise for up to $558 million to Intas Pharmaceuticals Ltd. - GlobeNewswire","headline":"Coherus Announces Agreement to Divest UDENYCA® Franchise for up to $558 million to Intas Pharmaceuticals Ltd.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxPYUZIbXRZZ1VfbUFIUEo0bkFyMlBlQzFYM2dGWFp0OFk3YVg0NHkyamVXNWdUTE5kTGxXQVc2OU55YmItVnlIa0xzbFk3QWFIY0VLWHg1ajdDM1ByN0d2ZU9PNFVOVTdPem9MMFRrUHFMSDNTZFRpLTBYbkZKejRBbjl6ZGsyNWEwbTZlTnQtR3dqbEF1dVc1OGV4Wm9QVnhwUG1iVzVwQUx6Zw?oc=5","date":"2024-12-03","type":"deal","source":"The Business Journals","summary":"Raleigh pharmaceutical company expands portfolio with $558M deal - The Business Journals","headline":"Raleigh pharmaceutical company expands portfolio with $558M deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTE1yZUdCN2NFVUtmN05QQ0oyYlJmMlJzbHk3TG5xdW83YVlKQTNFMUhXc2Rla3hkeWlQWkhPcXNsM0Y4ZUs5a2RleTA3Y2lhVEJL?oc=5","date":"2023-10-30","type":"pipeline","source":"CNN","summary":"symbol__ Stock Quote Price and Forecast - CNN","headline":"symbol__ Stock Quote Price and Forecast","sentiment":"neutral"}],"patents":[{"drugName":"Udenyca","drugSlug":"pegfilgrastim-cbqv","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":1400000000},{"drugName":"Yutiq","drugSlug":"fluocinolone-acetonide-intravitreal-implant","patentNumber":"","type":"Patent Cliff","expiryDate":"2032-06-01","territory":"US","annualRevenue":1100000000}],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Amgen","Pfizer","Sandoz"],"therapeuticFocus":["Oncology","Biosimilars"],"financials":{"source":"sec_edgar+yahoo","revenue":0,"revenuePeriod":"2018-12-31","revenueHistory":[{"value":0,"period":"2018-12-31"},{"value":1556000,"period":"2017-12-31"},{"value":190106000,"period":"2016-12-31"}],"grossProfit":116051000,"grossProfitHistory":[{"period":"2025-12-31","value":28358000},{"period":"2024-12-31","value":17662000},{"period":"2023-12-31","value":98252000},{"period":"2022-12-31","value":140959000}],"rdSpend":108888000,"rdSpendHistory":[{"period":"2025-12-31","value":108888000},{"period":"2024-12-31","value":91833000},{"period":"2023-12-31","value":109436000},{"period":"2022-12-31","value":199358000}],"sgaSpend":100604000,"operatingIncome":-181134000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-181134000},{"period":"2024-12-31","value":-199653000},{"period":"2023-12-31","value":-203199000},{"period":"2022-12-31","value":-256880000}],"netIncome":168024000,"netIncomeHistory":[{"period":"2025-12-31","value":168024000},{"period":"2024-12-31","value":28507000},{"period":"2023-12-31","value":-237892000},{"period":"2022-12-31","value":-291754000}],"eps":0.25,"epsHistory":[{"period":"2024-12-31","value":0.25},{"period":"2023-12-31","value":-2.53},{"period":"2022-12-31","value":-3.76},{"period":"2021-12-31","value":-3.81}],"cash":88879000,"cashHistory":[{"period":"2025-12-31","value":88879000},{"period":"2024-12-31","value":125987000},{"period":"2023-12-31","value":102891000},{"period":"2022-12-31","value":63547000}],"totalAssets":258343000,"totalLiabilities":197329000,"totalDebt":40336000,"equity":61014000,"operatingCashflow":-138513000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-138513000},{"period":"2024-12-31","value":-20440000},{"period":"2023-12-31","value":-174884000},{"period":"2022-12-31","value":-241124000}],"capex":-286000,"capexHistory":[{"period":"2023-12-31","value":-286000},{"period":"2022-12-31","value":-2039000},{"period":"2021-12-31","value":-1289000}],"freeCashflow":-138513000,"dividendsPaid":null,"buybacks":null,"employees":145,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":23609000,"ebit":-44098000,"ebitda":-43202000,"period":"2025-12-31","revenue":12748000,"epsBasic":-0.31,"netIncome":-37643000,"rdExpense":30974000,"epsDiluted":-0.31,"grossProfit":8703000,"operatingIncome":-45880000},{"sga":24931000,"ebit":-42192000,"ebitda":-41226000,"period":"2025-09-30","revenue":11571000,"epsBasic":-0.31,"netIncome":-35531000,"rdExpense":27252000,"epsDiluted":-0.31,"grossProfit":7850000,"operatingIncome":-44333000},{"sga":26039000,"ebit":-42585000,"ebitda":-41569000,"period":"2025-06-30","revenue":10254000,"epsBasic":2.57,"netIncome":297767000,"rdExpense":26306000,"epsDiluted":2.57,"grossProfit":6859000,"operatingIncome":-45486000},{"sga":26025000,"ebit":-45248000,"ebitda":-44202000,"period":"2025-03-31","revenue":7599000,"epsBasic":-0.49,"netIncome":-56569000,"rdExpense":24356000,"epsDiluted":-0.49,"grossProfit":4946000,"operatingIncome":-45435000},{"sga":41297000,"ebit":-45350000,"ebitda":-44317000,"period":"2024-12-31","revenue":54144000,"epsBasic":-0.44,"netIncome":-50696000,"rdExpense":21235000,"epsDiluted":-0.44,"grossProfit":20286000,"operatingIncome":-42246000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":1.66,"previousClose":1.71,"fiftyTwoWeekHigh":2.62,"fiftyTwoWeekLow":0.71,"fiftyTwoWeekRange":"0.71 - 2.616","fiftyDayAverage":1.75,"twoHundredDayAverage":1.55,"beta":1.02,"enterpriseValue":150320080,"forwardPE":-2,"priceToBook":2.88,"priceToSales":5.46,"enterpriseToRevenue":3.21,"enterpriseToEbitda":-0.92,"pegRatio":0,"ebitda":-163391008,"ebitdaMargin":0,"freeCashflow":-27062876,"operatingCashflow":-170572992,"totalDebt":54372000,"debtToEquity":69.2,"currentRatio":1.56,"returnOnAssets":-32.8,"returnOnEquity":0,"analystRating":"1.4 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":5,"targetMeanPrice":7.8,"targetHighPrice":12,"targetLowPrice":4,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":18.5,"institutionHeldPercent":32.1,"sharesOutstanding":154249900,"floatShares":132020947,"sharesShort":27818409,"shortRatio":29.32,"shortPercentOfFloat":18.6,"epsTrailing":-1.42,"epsForward":-0.81,"revenuePerShare":0.38,"bookValue":0.58,"officers":[{"age":70,"name":"Mr. Dennis M. Lanfear","title":"Chairman, President & CEO"},{"age":46,"name":"Mr. Bryan J. McMichael","title":"Chief Financial Officer"},{"age":null,"name":"Ms. Carrie  Graham","title":"Vice President of Investor Relations & Advocacy"},{"age":null,"name":"Mr. Andy  Rittenberg","title":"Chief Legal Officer"},{"age":62,"name":"Ms. Rebecca  Sunshine","title":"Chief Human Resources Officer"},{"age":null,"name":"Mr. Michael  Chen","title":"Senior Vice President of Commercial Analytics & Trade"},{"age":59,"name":"Dr. Theresa M. Lavallee Ph.D.","title":"Chief Development Officer & Chairman of Scientific Advisory Board"},{"age":57,"name":"Dr. Rosh  Dias M.D., MRCP","title":"Chief Medical Officer"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.coherus.com","phone":"650 649 3530"}}